Cellectis (CLLS)

• Market cap: $498M
• 1 day: 4.42%
• 5 days: 9.49%
• 1 month: 6.21%
• 3 months: 74.65%
• 6 months: 224.18%
• Year to date: 174.03%
• 1 year: 172.53%
• 5 years: -82.74%
• 10 years: -83.72%
• Sector: Healthcare
• Industry: Biotechnology

About: Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

Employees: 222